Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 15 · below the Ichimoku cloud · RSI 36 · MACD below its signal
| 9.14 | 52-week high | +54.92% |
| 7.74 | Previous month high | +31.19% |
| 7.07 | Previous week high | +19.83% |
| 6.57 | R3 (classic) | +11.41% |
| 6.46 | R2 (classic) | +9.44% |
| 6.34 | Previous day high | +7.46% |
| 6.32 | Previous month low | +7.12% |
| 6.31 | R1 (classic) | +7.01% |
| 6.20 | Pivot | +5.03% |
| 6.08 | Previous day low | +3.05% |
| 6.05 | S1 (classic) | +2.60% |
| 6.04 | Previous week low | +2.37% |
| 5.94 | S2 (classic) | +0.62% |
| 5.90 | Price now | |
| 5.79 | S3 (classic) | −1.81% |
| 5.44 | 52-week low | −7.80% |
None of the 29 investors followed here reported a position in GYRE in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a GYRE trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Ye WeiguoChief Operating Officer | Conversion of Exercise of derivative security at price 0.75 per share. | 11K | $8.25K |
| Jun 17, 2026 | Ye WeiguoChief Operating Officer | Sale at price 6.15 - 6.35 per share. | 11K | $68.70K |
| Jun 10, 2026 | Ye WeiguoChief Operating Officer | Conversion of Exercise of derivative security at price 0.75 per share. | 2.8K | $2.10K |
| Jun 10, 2026 | Ye WeiguoChief Operating Officer | Sale at price 6.17 per share. | 2.8K | $17.28K |
| Jun 9, 2026 | Ye WeiguoChief Operating Officer | Conversion of Exercise of derivative security at price 0.75 per share. | 20.9K | $15.69K |
| Jun 9, 2026 | Ye WeiguoChief Operating Officer | Sale at price 6.14 - 6.21 per share. | 20.9K | $128.89K |
| Jun 4, 2026 | Ye WeiguoChief Operating Officer | Conversion of Exercise of derivative security at price 0.75 per share. | 35K | $26.23K |
| Jun 4, 2026 | Ye WeiguoChief Operating Officer | Sale at price 6.13 - 6.40 per share. | 35K | $218.56K |
| May 25, 2026 | Ye WeiguoChief Operating Officer | Conversion of Exercise of derivative security at price 0.75 per share. | 7.5K | $5.63K |
| May 25, 2026 | Ye WeiguoChief Operating Officer | Sale at price 6.08 - 6.10 per share. | 7.5K | $45.68K |
| May 20, 2026 | Ye WeiguoChief Operating Officer | Conversion of Exercise of derivative security at price 0.75 per share. | 22.2K | $16.66K |
| May 20, 2026 | Ye WeiguoChief Operating Officer | Sale at price 6.15 per share. | 22.2K | $136.65K |
| May 18, 2026 | Ye WeiguoChief Operating Officer | Conversion of Exercise of derivative security at price 0.75 per share. | 9.3K | $6.99K |
| May 18, 2026 | Ye WeiguoChief Operating Officer | Sale at price 6.37 - 6.62 per share. | 9.3K | $59.42K |
| May 14, 2026 | Ye WeiguoChief Operating Officer | Conversion of Exercise of derivative security at price 0.75 per share. | 28.7K | $21.51K |
| May 14, 2026 | Ye WeiguoChief Operating Officer | Sale at price 6.65 - 6.91 per share. | 28.7K | $194.77K |
| May 5, 2026 | Luo YingChief Executive Officer | Sale at price 8.01 - 8.04 per share. | 10.3K | $82.93K |
| May 27, 2025 | Ma SongjiangPresident | Sale at price 10.07 - 10.28 per share. | 2.6K | $26.18K |
| May 22, 2025 | Ma SongjiangPresident | Sale at price 10.24 - 10.97 per share. | 2.2K | $23.80K |
| May 20, 2025 | Ma SongjiangPresident | Sale at price 10.83 - 11.25 per share. | 4K | $44.16K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 14.6 | 1.9 | -15.4 | 10.2 | -23.0 | 11.5 | -12.7 | 14.3 | 11.6 | -19.5 | −16.4% | ||
| 2025 | -4.9 | 0.8 | -33.4 | 26.4 | -7.1 | -19.0 | -4.1 | 9.8 | -3.6 | 3.9 | 0.0 | -8.9 | −41.7% |
| 2024 | -51.8 | 46.6 | -3.6 | -10.8 | -27.2 | 5.0 | 21.3 | -4.8 | -8.9 | 14.0 | -12.5 | -3.3 | −52.9% |
| 2023 | -47.2 | 7.1 | -30.0 | 0.0 | 4.8 | 59.1 | 8.6 | 47.4 | -14.3 | -6.5 | 249.5 | 9.2 | +223.1% |
| 2022 | -36.3 | 12.1 | 1.5 | -27.3 | 158.3 | 43.5 | -1.7 | 12.6 | -74.6 | 8.0 | 3.7 | -5.4 | −41.8% |
| 2021 | -10.5 | 6.7 | -16.4 | 0.0 | -15.3 | 1.4 | -6.0 | 12.5 | -10.3 | -20.0 | -63.5 | -24.2 | −85.6% |
| 2020 | 4.3 | -18.7 | -24.3 | 38.7 | 19.0 | -18.6 | -12.9 | 2.2 | -17.6 | 27.4 | 13.1 | 1.8 | −7.3% |
| 2019 | 11.4 | -3.1 | -4.8 | 7.5 | -9.9 | -6.2 | 11.1 | -22.1 | -23.0 | 10.8 | 0.2 | 25.0 | −13.7% |
| 2018 | 86.1 | -0.4 | 2.0 | 10.4 | -13.4 | -52.7 | -15.3 | 10.6 | -1.4 | -17.4 | 20.0 | -26.1 | −42.2% |
| 2017 | -10.8 | -22.2 | 39.3 | -43.7 | -10.9 | -1.7 | -11.2 | -18.9 | 51.0 | -2.6 | 41.8 | 95.1 | +39.9% |
| 2016 | -29.4 | -9.0 | -16.4 | -16.1 | 9.2 | -1.3 | -2.0 | -19.5 | 0.8 | -40.5 | -1.4 | -8.5 | −79.2% |
| 2015 | -4.6 | 4.8 | 12.9 | -22.6 | 19.6 | 1.5 | -11.8 | -31.5 | -60.5 | -17.2 | -22.3 | 4.3 | −83.0% |
| 2014 | 6.3 | 11.8 | -3.7 | -6.5 | -15.5 | 20.3 | -38.1 | -1.1 | -8.3 | -7.5 | 3.8 | 8.2 | −36.6% |
| 2013 | 2.5 | -3.6 | -1.2 | 7.7 | 22.1 | -24.2 | 17.1 | 2.4 | 3.7 | -10.5 | 21.1 | -27.8 | −5.3% |
| 2012 | 9.2 | 12.2 | -24.9 | -7.4 | -12.4 | 3.6 | 0.5 | 4.2 | 8.7 | -16.6 | 5.1 | 2.1 | −21.4% |
| 2011 | -2.8 | 11.3 | -7.3 | -9.1 | -6.9 | -6.4 | -3.0 | -20.4 | -7.9 | 17.3 | -57.3 | -25.8 | −79.0% |
| 2010 | 0.2 | -9.5 | 3.7 | 21.1 | -3.4 | -16.0 | 11.9 | -4.0 | 7.6 | 10.8 | -14.4 | 25.0 | +26.8% |
| 2009 | -41.6 | 13.5 | 13.6 | 34.0 | -20.9 | -13.7 | 338.0 | 38.9 | 43.4 | -12.3 | 24.9 | -10.7 | +487.1% |
| 2008 | -16.1 | 14.1 | -7.3 | 0.8 | 8.0 | -8.9 | 24.9 | 0.8 | -36.5 | 1.9 | -58.6 | 45.3 | −56.9% |
| 2007 | -3.6 | 4.0 | -8.3 | 18.4 | -5.9 | -1.3 | 8.7 | -2.9 | -6.9 | 4.6 | 2.1 | -14.0 | −8.7% |
TimeframesDown on all 4 timeframes: no timeframe is holding up.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
Buy / hold / sell counts
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.